Investigational drug · Phase 2
FXS5626
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Active Non-anterior, Non-infectious Uveitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "FXS5626"
First trial start
2026
Jan 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FXS5626", any sponsor or status.
Conditions studied
As listed on its trial records.
- Active Non-anterior, Non-infectious Uveitis
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "FXS5626" as an intervention, largest first.
- Phase II/III Study of FXS5626 in Participants With Non-segmental VitiligoPivotal-lookingNot yet recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07840820 · 480 participants (planned) · Start Oct 30, 2026 · Primary completion Nov 10, 2027
Drug: Intervention1: FXS5626 Tablets; Intervention2: FXS5626 Tablets and 4 more · For: Non-segmental Vitiligo
Sites: Shanghai, China
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIURecruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07552012 · 40 participants (planned) · Start Jan 29, 2026 · Primary completion Feb 28, 2027
Drug: FXS5626 tablet · For: Active Non-anterior, Non-infectious Uveitis
Sites: Chongqing, China
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
NCT07695779 · 28 participants (planned) · Start Aug 13, 2026 · Primary completion Sep 21, 2026
Drug: FXS5626 tablet; Placebo tablet · For: Evaluation of QTc Interval
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.